https://scholars.lib.ntu.edu.tw/handle/123456789/484018
標題: | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | 作者: | YU-YUN SHAO TSUNG-HAO LIU CHIUN HSU LI-CHUN LU YING-CHUN SHEN ZHONG-ZHE LIN ANN-LII CHENG CHIH-HUNG HSU |
關鍵字: | advanced hepatocellular carcinoma | alpha-fetoprotein | alpha-foetoprotein | biomarker | immune checkpoint inhibitors | immunotherapy;advanced hepatocellular carcinoma; alpha-fetoprotein; alpha-foetoprotein; biomarker; immune checkpoint inhibitors; immunotherapy | 公開日期: | 2019 | 出版社: | Wiley | 卷: | 39 | 期: | 11 | 來源出版物: | Liver International | 摘要: | © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Background: Post-treatment decline in serum alpha-foetoprotein (AFP) levels has been shown to predict the treatment efficacy of antiangiogenic therapy for advanced hepatocellular carcinoma (HCC). We explored whether a decline in AFP levels was also associated with treatment outcomes of immune checkpoint inhibitors (ICIs) in patients with advanced HCC. Methods: We reviewed all patients who received ICI therapy for advanced HCC. AFP response was evaluated in patients with the pretreatment AFP level of >20 ng/mL. We defined early AFP response as a >20% decline in serum AFP levels within the first 4 weeks of treatment initiation relative to pretreatment levels. We then studied whether early AFP response was associated with treatment outcomes. Results: Sixty patients were enrolled in this study; 43 of them were evaluable for early AFP response. The objective response rate of early AFP responders was significantly higher than that of early AFP nonresponders (73% vs. 14%, P <.001). Early AFP responders, compared with early AFP nonresponders, exhibited significantly longer overall survival (OS) (median, 28.0 vs 11.2 months, P =.048) and progression-free survival (PFS) (median, 15.2 vs 2.7 months, P =.002). After adjusting for other clinicopathological variables and treatments, early AFP response remained an independent predictor for longer OS (hazard ratio [HR] = 0.089, 95% confidence interval [CI] = 0.018-0.441; P =.003) and PFS (HR = 0.128, 95% CI = 0.041-0.399; P <.001). Conclusion: Early AFP response was associated with higher treatment efficacy of ICIs for advanced HCC. Additional validation studies are nonetheless warranted. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/484018 | ISSN: | 1478-3223 1478-3231 |
DOI: | 10.1111/liv.14210 61115170 |
SDG/關鍵字: | alpha fetoprotein; immune checkpoint inhibitor; immunological antineoplastic agent; unclassified drug; alpha fetoprotein; angiogenesis inhibitor; immunological antineoplastic agent; tumor marker; adult; advanced cancer; alpha fetoprotein blood level; Article; cancer immunotherapy; cancer survival; drug efficacy; female; human; liver cell carcinoma; major clinical study; male; middle aged; overall survival; progression free survival; treatment outcome; aged; blood; liver cell carcinoma; liver tumor; metabolism; mortality; survival analysis; Taiwan; urine; Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Survival Analysis; Taiwan; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。